A subset of altered genes and downstream pathways were selected for validation at the protein level. Immunohistochemistry (IHC) was performed at UCSF using a Ventana BenchMark autostainer. Sections were immunostained with commercially available antibodies, including anti-ATRX (Sigma-Aldrich; HPA001906), anti-IDH1 R132H (Dianova; H09), anti-EGFR (Dako; M3563, H11), anti-TP53 (Dako; M7001), anti-RB1 (RB1; BD Biosciences; 554136), anti–phospho-RPS6 (Ser240/244; Cell Signaling Technology; 2215), anti–phospho-AKT1S1 (PRAS40; Thr246; Cell Signaling Technology; 2997, C77D7), and anti–phospho-p44/42 MAPK1/MAPK3 (ERK1/2; Thr202/Tyr204; Cell Signaling Technology; 4370, D13.14.4E). All slides, including positive and negative controls, were reviewed and scored by a neuropathologist (J.J. Phillips).
Anti egfr
Manufactured by Agilent Technologies
Sourced in United States
The Anti-EGFR is a laboratory equipment product designed to detect and quantify the epidermal growth factor receptor (EGFR) in biological samples. It provides a reliable and accurate method for researchers to analyze EGFR levels, which is important for various applications in cell biology, cancer research, and drug development.
Automatically generated - may contain errors
Lab products found in correlation
Anti tp53, by Agilent Technologies (2 mentions)
Anti idh1 r132h, by Dianova (1 mentions)
Anti phospho rps6 ser240 244, by Cell Signaling Technology (1 mentions)
Anti atrx, by Merck Group (1 mentions)
Anti muc2, by Leica (1 mentions)
Anti smad4, by Santa Cruz Biotechnology (1 mentions)
Anti her2, by Agilent Technologies (1 mentions)
Anti cdx2, by BioGenex (1 mentions)
2 protocols using anti egfr
1
Protein Expression Analysis of Glioma Biomarkers
2
Immunophenotypic Evaluation of Pancreatobiliary Neoplasms
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Intraductal lesions and invasive carcinomas were evaluated separately by immunohistochemistry using the following antibodies that have been shown to be differentially expressed in pancreatobiliary neoplasms: 9,28-30 anti-MUC1 (Novocastra, Newcastle upon Tyne, UK; 1:160), anti-MUC2 (Novocastra; 1:100), anti-MUC5AC (Leica Microsystems, Bannockburn, IL, USA; 1:200), and anti-MUC6 (Leica Microsystems; 1:80), anti-EGFR (Dako, Carpinteria, CA, USA; RTU ready-to-use), anti-TP53 (Dako; 1:80), anti-HER2 (Dako; 1:80), anti-SMAD4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:400), anti-CDKN2A/p16 (CINtec, Ventana Medical Systems, Tucson, AZ, USA; ready-to-use), and anti-CDX2 (Biogenex, San Ramon, CA, USA; 1:200). All Modern Pathology (2015) 28, 1249-1264 immunolabeling was run on an automated immunostainer according to the company's protocols for open procedures with slight modifications. The immunohistochemical labeling of the antibodies listed above was evaluated as described before. 9
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!